Stem Cell Therapeutic and Research Reauthorization Act of 2025
The Stem Cell Therapeutic and Research Reauthorization Act of 2025 would reauthorize the Stem Cell Therapeutic and Research Act of 2005 and make targeted changes to funding and program duration. The bill primarily maintains federal support for stem cell transplantation and cord blood initiatives, while adjusting appropriations for the C.W. Young Cell Transplantation Program and extending the Cord Blood Inventory program. Specifically, it sets a base appropriation for the transplantation program and adds a higher annual funding level for FY 2027–2031, and it extends the Cord Blood Inventory program’s end date from 2026 to 2031. The overarching goal is to sustain and expand access to stem cell therapies and to ensure a reliable supply of cord blood for transplantation and research.
Key Points
- 1Reauthorizes the Stem Cell Therapeutic and Research Act of 2005, ensuring continued federal support for related programs.
- 2Funding for the C.W. Young Cell Transplantation Program is updated to a base of $31,009,000, with an increased level of $33,009,000 for each fiscal year from 2027 through 2031.
- 3The Cord Blood Inventory program end date is extended from 2026 to 2031, effectively prolonging federal support and inventory activities.
- 4The act carries the short title “Stem Cell Therapeutic and Research Reauthorization Act of 2025.”
- 5The bill was introduced in the House (Sept. 4, 2025) and referred to the Committee on Energy and Commerce; funding remains subject to annual appropriations.